{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Cycle 1 (Pre-dose nivolumab)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"First Positive Cycle (pre-dose) - Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"First Positive Cycle (pre-dose) - Cycle 8"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Any positive post-baseline"}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"groups":[{"description":"BV in combination with nivolumab as frontline therapy in adults aged 60 and above with cHL. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle. Nivolumab (3 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle.","id":"OG000","title":"Part D"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Subject with baseline negative anti-drug antibody (ADA)","reportingStatus":"POSTED","timeFrame":"Up to 30 months","title":"Number of Participants With Nivolumab Antitherapeutic Antibodies (ATA) (Part D Only)","type":"SECONDARY","unitOfMeasure":"Participants"}